Description:

ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Link:

http://clinicaltrials.gov/ct2/show/record/NCT00952588

Keywords:
Versions (4) ▾
  1. 11/14/11
  2. 12/6/13
  3. 4/11/14
  4. 12/16/14
Uploaded on:

December 16, 2014

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility AZD1152 and LDAC in AML

Eligibility AZD1152 and LDAC in AML

  1. StudyEvent: Eligibility
    1. Eligibility AZD1152 and LDAC in AML
Inclusion criteria
Provision of written informed consent
Newly diagnosed male or female patients aged 60 and over
De Novo or Secondary AML
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
Exclusion criteria
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
Administration of LDAC is clinically contraindicated
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
Patients with blast crisis of chronic myeloid leukaemia